Alembic Pharmaceuticals Launches Pivya® in US Market

Alembic Pharmaceuticals Limited has reported the first prescription-based sale of Pivya® (pivmecillinam) tablets in the United States. This follows the commercial launch of the product through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of Alembic Pharmaceuticals. Pivya® is an oral prescription antibiotic used for the treatment of uncomplicated urinary tract infections (uUTIs) in women.

The filing does not specify financial terms or revenue figures related to the launch of Pivya®. The focus is on establishing a presence in the US branded pharmaceuticals market. Alembic Pharmaceuticals aims to leverage its entry into this segment to build a broader branded portfolio over time. The company has not disclosed specific financial projections or targets associated with this launch.

Pivya® is indicated for female patients aged 18 years and older with uncomplicated urinary tract infections caused by specific bacterial isolates. The product is marketed as a first-line oral antibiotic option in a segment that has seen limited new product introductions over the past decade. Alembic Pharmaceuticals has established an initial sales footprint across key territories in the US, targeting high-prescribing physicians in women’s health. The company plans a phased expansion of its field force as prescription momentum builds, supported by targeted physician education and market access initiatives.

The market for uncomplicated urinary tract infections in the US is significant, with approximately 30 million prescriptions annually. The introduction of Pivya® aims to address the need for effective first-line therapies in this category. Alembic Pharmaceuticals is positioning itself to participate in this large and stable therapeutic market with a clinically established product.

The commercial launch of Pivya® represents a strategic step for Alembic Pharmaceuticals as it expands its presence in the US market. The company continues to focus on a balanced approach across generics, specialty products, and branded pharmaceuticals. The launch complements Alembic’s established generics franchise and supports its strategy of disciplined investments for sustainable growth and long-term value creation.

Alembic Pharmaceuticals Limited is a research and development-focused pharmaceutical company with a history dating back to 1907. The company manufactures and markets generic pharmaceutical products globally and is recognized as a leader in branded generics in India. Alembic Pharmaceuticals is committed to expanding its presence in international markets, including the US, through strategic initiatives and product launches.